Swedencare AB (publ) (SECARE.ST)
SEK 48.8
(-2.4%)
SEK 48.8
(-2.4%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.32 Billion SEK | 27.07% |
| 2022 | 1.82 Billion SEK | 137.46% |
| 2021 | 770.44 Million SEK | 221.09% |
| 2020 | 239.94 Million SEK | 89.12% |
| 2019 | 126.87 Million SEK | 27.98% |
| 2018 | 99.13 Million SEK | 15.73% |
| 2017 | 85.66 Million SEK | 58.18% |
| 2016 | 54.15 Million SEK | 17.49% |
| 2015 | 46.09 Million SEK | 90.75% |
| 2014 | 24.16 Million SEK | 32.28% |
| 2013 | 18.26 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 630.5 Million SEK | 5.28% |
| 2024 Q1 | 598.9 Million SEK | -4.51% |
| 2024 Q3 | 643.6 Million SEK | 2.08% |
| 2023 Q1 | 523.6 Million SEK | 5.92% |
| 2023 FY | 2.32 Billion SEK | 27.07% |
| 2023 Q2 | 573.9 Million SEK | 9.61% |
| 2023 Q3 | 611.7 Million SEK | 6.59% |
| 2023 Q4 | 627.2 Million SEK | 2.53% |
| 2022 Q1 | 380.15 Million SEK | 50.4% |
| 2022 FY | 1.82 Billion SEK | 137.46% |
| 2022 Q3 | 483.61 Million SEK | 2.61% |
| 2022 Q4 | 494.35 Million SEK | 2.22% |
| 2022 Q2 | 471.33 Million SEK | 23.99% |
| 2021 Q2 | 160.24 Million SEK | 19.5% |
| 2021 Q3 | 223.32 Million SEK | 39.36% |
| 2021 Q4 | 252.76 Million SEK | 13.18% |
| 2021 Q1 | 134.09 Million SEK | 33.53% |
| 2021 FY | 770.44 Million SEK | 221.09% |
| 2020 Q3 | 69.56 Million SEK | 116.66% |
| 2020 Q2 | 32.1 Million SEK | -15.17% |
| 2020 FY | 239.94 Million SEK | 89.12% |
| 2020 Q4 | 100.42 Million SEK | 44.36% |
| 2020 Q1 | 37.85 Million SEK | 11.04% |
| 2019 Q3 | 31.76 Million SEK | 4.29% |
| 2019 Q2 | 30.46 Million SEK | -0.31% |
| 2019 Q1 | 30.55 Million SEK | 11.0% |
| 2019 FY | 126.87 Million SEK | 27.98% |
| 2019 Q4 | 34.08 Million SEK | 7.3% |
| 2018 Q1 | 21.79 Million SEK | -4.43% |
| 2018 Q3 | 24.06 Million SEK | -6.52% |
| 2018 Q4 | 27.52 Million SEK | 14.39% |
| 2018 FY | 99.13 Million SEK | 15.73% |
| 2018 Q2 | 25.74 Million SEK | 18.1% |
| 2017 Q3 | 21.59 Million SEK | 17.69% |
| 2017 Q4 | 22.8 Million SEK | 5.63% |
| 2017 FY | 85.66 Million SEK | 58.18% |
| 2017 Q1 | 22.91 Million SEK | 47.73% |
| 2017 Q2 | 18.34 Million SEK | -19.91% |
| 2016 Q1 | 13.74 Million SEK | -42.96% |
| 2016 Q4 | 15.5 Million SEK | 14.95% |
| 2016 Q3 | 13.49 Million SEK | 20.49% |
| 2016 Q2 | 11.19 Million SEK | -18.54% |
| 2016 FY | 54.15 Million SEK | 17.49% |
| 2015 Q1 | 6.25 Million SEK | 0.0% |
| 2015 FY | 46.09 Million SEK | 90.75% |
| 2015 Q4 | 24.09 Million SEK | 229.07% |
| 2015 Q2 | 8.43 Million SEK | 34.79% |
| 2015 Q3 | 7.32 Million SEK | -13.13% |
| 2014 FY | 24.16 Million SEK | 32.28% |
| 2013 FY | 18.26 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | -79.297% |
| Enzymatica AB (publ) | 50.9 Million SEK | -4466.635% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -171078.203% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | -7826.484% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | -6211.874% |
| ODI Pharma AB | 22.44 Million SEK | -10255.892% |
| Orexo AB (publ) | 638.8 Million SEK | -263.901% |
| Probi AB (publ) | 627.68 Million SEK | -270.344% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 89.493% |
| Toleranzia AB | 50.92 Million SEK | -4465.2% |
| Vivesto AB | 1.01 Million SEK | -228924.631% |